Prevalence and clinical significance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China

Xue Mei1 · Hai Li2,3 · Guohong Deng4 · Xianbo Wang5 · Xin Zheng6 · Yan Huang7 · Jinjun Chen8 · Zhongji Meng9 · Yanhang Gao10 · Feng Liu11 · Xiaobo Lu12 · Yu Shi13,14,15 · Yubao Zheng16 · Huadong Yan17 · Weituo Zhang18 · Liang Qiao2,3 · Wenyi Gu2,3 · Yan Zhang2,3 · Xiaomei Xiang4 · Yi Zhou4 · Shuning Sun4 · Yixin Hou5 · Qun Zhang5 · Yan Xiong9 · Congcong Zou6 · Jun Chen7 · Zebing Huang7 · Beiling Li8 · Xiuhua Jiang8 · Guotao Zhong8 · Haiyu Wang8 · Yuanyuan Chen9 · Sen Luo9 · Na Gao10 · Chunyan Liu10 · Jing Li11 · Tao Li11 · Rongjiong Zheng12 · Xinyi Zhou12 · Haotang Ren13,14,15 · Wei Yuan1 · Zhiping Qian1

Received: 25 August 2021 / Accepted: 22 November 2021 / Published online: 17 January 2022
© Asian Pacific Association for the Study of the Liver 2021

Abstract
Background No reports exist regarding the prevalence of different Na levels and their relationship with 90-day prognosis in hospitalized patients with acute-on-chronic liver disease (AoCLD) in China. Therefore, the benefit of hyponatremia correction in AoCLD patients remains unclear.

Methods We prospectively collected the data of 3970 patients with AoCLD from the CATCH-LIFE cohort in China. The prevalence of different Na levels (≤ 120; 120–135; 135–145; > 145) and their relationship with 90-day prognosis were analyzed. For hyponatremic patients, we measured Na levels on days 4 and 7 and compared their characteristics, based on whether hyponatremia was corrected.

Results A total of 3880 patients were involved; 712 of those developed adverse outcomes within 90 days. There were 80 (2.06%) hypernatremic, 28 (0.72%) severe hyponatremic, and 813 (20.95%) mild hyponatremic patients at admission. After adjusting for all confounding factors, the risk of 90-day adverse outcomes decreased by 5% (odds ratio [OR] 0.95; 95% confidence interval [CI] 0.93–0.97; \( p < 0.001 \)), 24% (OR 0.76; 95% CI 0.70–0.84; \( p < 0.001 \)), and 42% (OR 0.58; 95% CI 0.49–0.70; \( p < 0.001 \)) as Na level increased by 1, 5, and 10 mmol/L, respectively. Noncorrection of hyponatremia on days 4 and 7 was associated with 2.05-fold (hazard ratio [HR], 2.05; 95% CI, 1.50–2.79; \( p < 0.001 \)) and 1.46-fold (HR 1.46; 95% CI 1.05–2.02; \( p = 0.028 \)) higher risk of adverse outcomes.

Conclusions Hyponatremia was an independent risk factor for a poor 90-day prognosis in patients with AoCLD. Failure to correct hyponatremia in a week after admission was often associated with increased mortality. (ClinicalTrial.gov number: NCT02457637, NCT03641872).

Clinical Trial Numbers This study is registered at Shanghai www.clinicaltrials.org (NCT02457637 and NCT03641872).

Keywords Prevalence · Significance · Serum sodium · Na · Hyponatremia · Adverse outcome · 90-day · Prognosis · Acute-on-chronic liver disease · AoCLD

Introduction

With the development of the global economy and the popularization of antiviral drugs, chronic hepatitis B and C have been gradually controlled; however, the incidence of fatty liver disease and drug-induced liver injury is increasing annually [1]. Chronic liver disease (CLD) remains a frequent cause of death. In 2017, 1.32 million people died directly because of liver cirrhosis, which accounts for 2–4% of...
deaths annually [2, 3]. During the coronavirus disease 2019 (COVID-19) pandemic, mortality was also significantly higher in patients with CLD than in those without CLD [4]. To improve the prognosis of cirrhotic patients, the model for end-stage liver disease (MELD) score has been used since 2002 to rank and prioritize liver transplantation (LT) candidates [5, 6]. Since then, some researchers have found that hyponatremia was an independent prognostic factor in cirrhotic patients [7–9]. Therefore, more optimized prediction tools, such as the Model for end-stage liver disease-sodium (MELD-Na) and United Kingdom Model for end-stage liver disease (UKELD) scores, have been developed [9–11]. Most previous studies confirm that serum sodium (Na) is closely associated with the severity and complications of liver cirrhosis and affects a patient’s health-related quality of life (HRQOL) and perioperative mortality after transplantation [12, 13]. Hyponatremic patients have longer hospital stays and higher hospitalization rates [14]. The subsequent mortality of patients with hyponatremia is also significantly increased, regardless of accompanying diseases [15].

An abnormal Na level seems to be a common electrolyte disorder in clinical practice, but it often indicates a risk of other complications. However, there was insufficient information regarding the prevalence of different Na levels and their relationship with 90-day prognosis in hospitalized patients with acute-on-chronic liver disease (AoCLD) in areas with a high prevalence of hepatitis B virus (HBV) in China [16]. The benefit of hyponatremia correction at 4–7 days after admission in patients with AoCLD remains unclear. Therefore, this study aimed to describe the prevalence and clinical significance of Na variability in this population.

**Methods**

**Patients**

In total, 3970 patients with AoCLD were included in this study from the CATCH-LIFE cohort [16–18], which was a multicenter prospective cohort study conducted by the Chinese Chronic Liver Failure (CLIF) Federation (comprising 15 tertiary hospitals in a high HBV epidemic area) conducted from 2015 to 2016 and from 2018 to 2019. The ethics committee of Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University (Shanghai, China) approved the study and registered it at Shanghai www.clinicaltrials.org (NCT02457637, NCT03641872). The study was performed in accordance with the standards of the Declaration of Helsinki. Written informed consent was obtained from all patients. All authors have access to the study data and reviewed and approved the final manuscript.

**Related event definitions**

AoCLD is a nonmalignant CLD with acute decompensation (AD) or acute liver injury (ALI). CLD is considered cirrhotic or noncirrhotic liver disease with a history of liver dysfunction lasting > 6 months. Cirrhosis was diagnosed based on findings of computed tomography/magnetic resonance imaging (CT/MRI) scans and laboratory tests, clinical symptoms, and history of liver disease. A diagnosis of AD requires individuals to have at least one acute decompensation event, which includes gastrointestinal hemorrhage, hepatic encephalopathy, overt ascites, bacterial infection (e.g., spontaneous peritonitis and pneumonia), or jaundice [i.e., total bilirubin (TBIL) > 5 mg/dL] within 1 month before enrollment. ALI was defined as alanine aminotransferase or aspartate aminotransferase levels three times more than the upper limit of the normal range (ULN) (but < 40 IU/L) or a total bilirubin level two times more than the ULN (but < 1 mg/dL) within a week. The definition of 90-day adverse outcomes or poor prognosis was death or LT.

Based on the definition of hyponatremia [19–21], all patients were classified into four groups as follows: severe hyponatremia (Na level, ≤ 120 mmol/L), mild hyponatremia (Na level, > 120 and < 135 mmol/L), normal serum sodium (Na level, ≥ 135 and ≤ 145 mmol/L), and hypernatremia (Na level > 145 mmol/L) groups. The exclusion criteria were as follows: (1) age < 15 years or > 80 years, (2) pregnancy, (3) severe chronic extrahepatic disease, and (4) hepatocellular carcinoma or other liver malignancies before or during admission, and extrahepatic malignancies.

**Data collection**

Data pertaining to demographics, medical history, biochemical indicators, and imaging data were prospectively recorded at each center. After admission, all patients were followed up for 90 days, and the outcomes were recorded (endpoint events included LT or death).

**Statistical analysis**

Data were summarized using the appropriate descriptive statistics (i.e., median and interquartile range for continuous variables and frequency and percentage for categorical parameters). The Mann–Whitney U test was used for non-parametric pairwise comparisons, and the Chi-square test or Fisher’s exact test was used for categorical variables. For more than three variables, non-normal continuous variables were analyzed using the Kruskal–Wallis test.

We estimated the potential confounding factors that impact the prognosis of AoCLD patients by univariate and
subgroup analyses, which showed a statistically significant interaction ($p < 0.05$). When Na level was used as a continuous variable and a categorical variable, multiple covariates (i.e., potential confounding factors) were gradually introduced to analyze the influence of unadjusted and multivariate-adjusted Na level on 90-day adverse outcomes using the backward stepwise (likelihood ratio) method of binary logistic regression. Furthermore, a generalized additive model and smooth curve fitting were used to describe the relationship between Na level and 90-day adverse outcomes. Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. The main objective of this study was to assess the effect of Na level on the risk of 90-day adverse outcomes.

All statistical tests were two-tailed, and bilateral $\alpha$ of $<0.05$ was statistically significant. SPSS 25 (IBM, Seattle, WA, USA) and R version 4.0.4 software (http://www.r-project.org) were used for statistical analysis and plots.

Results

Characteristics of the study population

Finally, 3880 patients were analyzed in this study according to the inclusion and exclusion criteria (Fig. 1). We determined not more than 5% missing data for each variable used on admission (Supplementary Fig. 1). The prevalence of different Na levels (i.e., hyponatremia, normonatremia, hypernatremia) in patients with AoCLD and their characteristics are summarized in Table 1. The incidence of alcoholic liver disease and chronic hepatitis B were significantly different between the Na level groups ($p < 0.05$).

The lower the Na level, the higher the proportion of liver cirrhosis and the worse the liver function score, including MELD, sequential organ failure assessment (SOFA), Child–Pugh, and other related scores ($p < 0.05$). At admission, patients in the hyponatremic groups had a higher frequency of AD events (e.g., ascites, hepatic encephalopathy, infection, and jaundice, but not gastrointestinal bleeding; $p < 0.05$). Moreover, TBIL, international normalized ratio (INR), serum creatinine (CR) level, blood urea nitrogen, and white blood cell (WBC) counts were also higher in the hyponatremic groups ($p < 0.05$) (Table 1; Supplementary Fig. 2).

Ninety-day adverse outcomes

Among the 3880 patients, 712 (18.35%) had 90-day adverse outcomes (498 deaths and 214 LT). The severe hyponatremia group had the highest incidence of adverse outcomes (50.0%, $p < 0.05$) and LT-free mortality (48.2%, $p < 0.05$) (Table 1; Supplementary Fig. 3a).

Relationship between hyponatremia and 90-day adverse outcomes

Interactions between Na level and 90-day adverse outcomes were observed in subgroups with different TBIL levels, INR, CR levels, age, and incidence of cirrhosis, ascites, infection, and hepatic encephalopathy ($p < 0.05$), but not for sex and etiology (Supplementary Fig. 3b). Among patients with hepatitis B, regardless of receiving nucleotide/nucleoside analogs (NUCs) before admission, Na level remained an independent risk factor for 90-day adverse outcomes. We constructed four models (i.e., 1 unadjusted and 3 adjusted) to evaluate the relationship between Na level and 90-day adverse outcomes. Univariate and multivariate analyses showed that Na levels were inversely associated with the incidence of 90-day adverse outcomes (for trend, $p < 0.001$) (Table 2). After adjusting for all confounding factors that may affect the outcomes, the severe hyponatremia group had the highest risk of 90-day adverse outcomes (odds ratio [OR] 2.36; 95% confidence interval [CI] 0.98–5.67; $p = 0.056$). Therefore, hyponatremia was an independent risk factor for 90-day adverse outcomes in patients with AoCLD. When Na level was analyzed as a continuous variable, the risk of 90-day adverse outcomes decreased by 5% (OR 0.95; 95% CI 0.93–0.97; $p < 0.001$), 24% (OR, 0.76; 95% CI 0.70–0.84; $p < 0.001$), and 42% (OR 0.58; 95% CI 0.49–0.70; $p < 0.001$) for Na level increasing by 1, 5, and 10 mmol/L, respectively, after adjusting for all confounding factors. Similar results were obtained for the cirrhosis subgroup (Table 3). In the noncirrhotic population, hyponatremia increased the risk of 90-day adverse outcomes; however, no significant difference existed after adjusting for all confounding factors (Table 4). Finally, we found that the results were consistent with the original data, based on sensitivity analysis of multiple imputation missing values (Supplementary Tables 1–3).

The generalized additive model showed that, when the Na level was $< 135$ mmol/L, the relationship between the Na level and the incidence of 90-day adverse outcomes was approximately linear and negatively correlated, regardless of the correction of the confounding factors (Fig. 2a,b). However, when the Na level was $> 135$ mmol/L, the risk of 90-day adverse outcomes did not significantly increase. Therefore, a Na level of 135 mmol/L could be used as the cut-off value. The risk of 90-day adverse outcomes in patients with hyponatremia (Na level $< 135$ mmol/L) was significantly higher than that in patients without hyponatremia (Na level $\geq 135$ mmol/L) (hazard ratio [HR], 3.01;
Fig. 1 Flow chart of all enrolled patients after applying the inclusion and exclusion criteria
### Table 1  Baseline characteristics of patients with AoCLD among different Na level groups

| Characteristics | Na ≤ 120 mmol/L (n=28) | 120 < Na ≤ 135 mmol/L (n=813) | 135 ≤ Na ≤ 145 mmol/L (n=2959) | Na > 145 mmol/L (n=80) | p value |
|-----------------|-------------------------|---------------------------------|--------------------------------|------------------------|---------|
| **Demographics** |                         |                                 |                                |                        |         |
| Age (years)     | 51.57 [43.14–59.28]     | 50.86 [43–58.85]                | 47.96 [39.15–57.13]           | 55 [43.38–62]         | 0.000   |
| Sex (male)      | 16 (57.1)               | 621 (76.4)                      | 2170 (73.3)                   | 51 (63.7)             | 0.010   |
| **Etiology**    |                         |                                 |                                |                        |         |
| Alcoholic       | 7 (25)                  | 95 (11.7)                       | 229 (7.7)                     | 8 (10)                | 0.000   |
| HBV            | 11 (39.3)               | 429 (52.8)                      | 1705 (57.6)                   | 41 (51.2)             | 0.016   |
| AIH            | 2 (7.1)                 | 62 (7.6)                        | 275 (9.3)                     | 11 (13.8)             | 0.228   |
| HCV            | 1 (3.6)                 | 20 (2.5)                        | 82 (2.8)                      | 4 (5)                 | 0.669   |
| NAFLD          | 0 (0)                   | 1 (0.1)                         | 38 (1.3)                      | 0 (0)                 | 0.021   |
| Schistosomiasis | 0 (0)                   | 7 (0.9)                         | 16 (0.5)                      | 2 (2.5)               | 0.134   |
| HBV + Alcoholic | 4 (14.3)               | 102 (12.5)                      | 241 (8.1)                     | 4 (5)                 | 0.001   |
| **Cirrhosis status** |                 |                                 |                                |                        |         |
| non-cirrhosis   | 1 (3.6)                 | 114 (14)                        | 969 (32.7)                    | 22 (27.5)             | 0.000   |
| compensated cirrhosis | 8 (28.6)             | 370 (45.5)                      | 1221 (41.3)                   | 26 (32.5)             | 0.000   |
| decompensated cirrhosis | 19 (67.9)         | 329 (40.5)                      | 769 (26)                      | 32 (40)               | 0.000   |
| **Acute decompensation** |             |                                 |                                |                        |         |
| HE             |                         |                                 |                                |                        | 0.000   |
| Grade 0        | 22 (78.6)               | 709 (87.2)                      | 2758 (93.2)                   | 56 (30)               |         |
| Grade 1        | 2 (7.1)                 | 27 (3.3)                        | 92 (3.1)                      | 5 (6.3)               |         |
| Grade 2        | 4 (14.3)                | 50 (6.2)                        | 72 (2.4)                      | 10 (12.5)             |         |
| Grade 3        | 0 (0)                   | 23 (2.8)                        | 26 (0.9)                      | 5 (6.3)               |         |
| Grade 4        | 0 (0)                   | 4 (0.5)                         | 11 (0.4)                      | 4 (5)                 |         |
| Infection      | 10 (35.7)               | 306 (37.6)                      | 511 (17.3)                    | 12 (15)               | 0.000   |
| Ascites        | 17 (60.7)               | 546 (67.2)                      | 1236 (41.8)                   | 32 (40)               | 0.000   |
| Gastrointestinal bleeding | 4 (14.3)               | 113 (13.9)                      | 436 (14.7)                    | 15 (18.8)             | 0.707   |
| Jaundice       | 20 (71.4)               | 543 (66.8)                      | 1250 (42.2)                   | 22 (27.5)             | 0.000   |
| **Laboratory tests** |                 |                                 |                                |                        |         |
| ALT (U/L)      | 73.3 [39.23–135.63]     | 60.2 [29.8–192]                 | 106 [33.1–472]                | 53 [26–241]           | 0.000   |
| AST (U/L)      | 113.75 [41.28–172.9]    | 96 [49.5–208.05]                | 112 [47–299.35]               | 84.9 [35.6–161]       | 0.000   |
| ALB (g/L)      | 30.4 [26.4–35.08]       | 29.6 [25.7–33.25]               | 32.9 [28.8–37.4]              | 32.9 [28.25–37.6]     | 0.000   |
| TBIL (mg/dL)   | 12.21 [3.37–26.84]      | 11.11 [3.19–22.96]              | 3.42 [1.44–12.14]             | 2.04 [1.25–6.57]      | 0.000   |
| INR            | 2.04 [1.37–2.69]        | 1.68 [1.36–2.23]                | 1.37 [1.16–1.7]               | 1.31 [1.16–1.62]      | 0.000   |
| CR (mg/dL)     | 0.84 [0.58–1.35]        | 0.81 [0.67–1.08]                | 0.76 [0.63–0.91]              | 0.8 [0.6–0.96]        | 0.000   |
| BUN (mmol/L)   | 9.53 [4.57–14.95]       | 5.81 [4.04–8.6]                 | 4.3 [3.3–5.89]                | 5.3 [3.83–9.23]       | 0.000   |
| WBC (×10^9/L)  | 7.38 [3.6–11.67]        | 6.2 [4.17–9.21]                 | 4.8 [3.5–6.54]                | 4.38 [3.15–8.82]      | 0.000   |
| PLT (×10^9/L)  | 67 [45.5–122]           | 79 [52–121]                     | 98 [60–150.2]                 | 74 [51–131]           | 0.000   |
| HB (g/L)       | 106.5 [81.5–128.3]      | 108 [86–127]                    | 120 [99–137]                  | 117 [92–130]          | 0.000   |
| K (mmol/L)     | 4.47 [3.52–5.05]        | 3.9 [3.5–4.3]                   | 3.85 [3.54–4.17]              | 3.8 [3.3–4.1]         | 0.093   |
| PaO₂/FiO₂ (%)  | 476.19 [466.67–476.19]  | 471.43 [466.67–476.19]          | 476.19 [466.67–476.19]        | 476.19 [466.67–476.19] | 0.000   |
| MAP (mmHg)     | 86.67 [80.5–93.33]      | 88 [80.67–93.33]                | 89 [83.33–95]                 | 93.33 [86.67–98]      | 0.000   |
| **Scores**     |                         |                                 |                                |                        |         |
| MELD           | 23 [17.5–31]            | 21 [15–27]                      | 15 [10–21]                    | 12 [10–17]            | 0.000   |
| MELD_Na        | 33 [30.25–37]           | 25 [20–30]                      | 15 [10–22]                    | 7 [5–13]              | 0.000   |
| iMELD          | 55 [51–64.5]            | 44 [38–50]                      | 32 [26–38]                    | 26 [23–33]            | 0.000   |
95% CI 2.50–3.62; \( p < 0.001 \) (Fig. 2c), regardless of cirrhosis (Supplementary Fig. 4a, b).

**Dynamic changes in Na level on days 4 and 7 related to 90-day adverse outcomes**

If the Na level of patients increased to > 135 mmol/L, hyponatremia was corrected. The 90-day survival rate was significantly higher in the corrected group than in the uncorrected group, regardless of the correction of hyponatremia on days 4 or 7 after admission (75.2% vs. 56.1% and 75.4% vs. 66.4%; \( p < 0.05 \)) (Fig. 2d, e).

On day 4, the MELD, SOFA, and Child–Pugh scores, baseline WBC, and baseline TBIL, INR, and CR levels in the uncorrected group were significantly higher than those in the corrected group. The corrected group had a lower

---

**Table 1** (continued)

| Characteristics | Na ≤ 120 mmol/L \((n=28)\) | 120 < Na < 135 mmol/L \((n=813)\) | 135 ≤ Na ≤ 145 mmol/L \((n=2959)\) | Na > 145 mmol/L \((n=80)\) | \( p \) value |
|-----------------|-----------------------------|---------------------------------|---------------------------------|-----------------------------|----------------|
|                 | CLIF_SOFA                   | SOFA                           | CHILD_PUGH                      |                             |                |
|                 | 6 [5.25–8]                  | 10 [9–11]                      | 10.5 [9–11.75]                  |                             |                |
| **Outcomes**    | 90-day adverse outcomes     | 14 (50)                        | 14 (36.4)                       |                             |                |
|                 | 90-day death                | 212 (26.1)                     | 286 (35.2)                      |                             |                |
|                 | 90-day LT                   | 74 (9.1)                       | 137 (4.6)                       |                             |                |

Na serum sodium, HBV hepatitis B virus, AIH autoimmune hepatitis, HCV hepatitis C virus, HE hepatic encephalopathy, ALT aspartate aminotransferase, AST alanine aminotransferase, ALB albumin, TBIL total bilirubin, INR international normalized ratio, CR serum creatinine, BUN blood urea nitrogen, WBC white blood cell, HB hemoglobin, PLT platelet, K serum potassium, PaO2 arterial partial pressure of oxygen, FiO2 fraction of inspired O2, MAP mean arterial pressure, MELD model for end-stage liver disease, iMELD integrated MELD, SOFA Sequential Organ Failure Assessment, CLIF-SOFA Chronic Liver Failure Assessment, Child–Pugh Child–Turcotte–Pugh, LT liver transplantation

*Continuous variables are presented as median (interquartile range); categorical variables are presented as n(percentage)*

---

**Table 2** Adjusted effects of Na level on 90-day adverse outcomes (death or LT) in all patients \((n=3880)\)

| Number of 90-day adverse outcomes (percentage) | OR, 95% CI, \( p \) value | OR, 95% CI, \( p \) value | OR, 95% CI, \( p \) value | OR, 95% CI, \( p \) value |
|-----------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Na (continuous)                                | 0.88 (0.87,0.90)<0.001      | 0.90 (0.88,0.91)<0.001      | 0.91 (0.89,0.92)<0.001      | 0.95 (0.93,0.97)<0.001      |
| Na-categorical                                 |                             |                             |                             |                             |
| (Na 135–145 mmol/L)                            | 398 (13.5)                  | 1.00                        | 1.00                        | 1.00                        |
| (Na > 145 mmol/L)                              | 14 (17.5)                   | 1.37 (1.02,1.83) 0.039      | 1.30 (0.72,2.36) 0.386      | 0.91 (0.89,1.85) 0.991      | 1.21 (0.63,2.34) 0.565 |
| (Na 120–135 mmol/L)                            | 286 (35.2)                  | 3.49 (2.92,4.18) 0.001      | 3.02 (2.52,3.63) 0.001      | 2.56 (2.12,3.09) 0.001      | 1.72 (1.39,2.13) 0.001 |
| (Na ≤ 120 mmol/L)                              | 14 (50)                     | 6.44 (3.05,13.60) 0.001     | 5.19 (2.45,11.03) 0.001     | 4.41 (2.03,9.58) 0.001      | 2.36 (0.98,5.67) 0.056 |
| \( p \) value for trend*                       | <0.001                      | <0.001                      | <0.001                      | <0.001                      |
| Na (continuous 5 mmol/L decrease)              | 0.54 (0.50,0.59) 0.001      | 0.58 (0.53,0.63) 0.001      | 0.62 (0.57,0.67) 0.001      | 0.76 (0.70,0.84) 0.001      |
| Na (continuous 10 mmol/L decrease)             | 0.29 (0.25,0.34) 0.001      | 0.33 (0.28,0.39) 0.001      | 0.38 (0.32,0.45) 0.001      | 0.58 (0.49,0.70) 0.001      |

*Continuous variables are presented as median (interquartile range); categorical variables are presented as n(percentage)*

---

Model I Un-adjusted;  
Model II Adjusted for age, sex, cirrhosis;  
Model III Adjusted for age, sex, cirrhosis, HE, ascites, infection;  
Model IV Adjusted for age, sex, cirrhosis, HE, ascites, infection, TBIL, INR, CR;  
CI confidence interval  
*Test for trend based on variables containing median value for each group*
Table 3  Adjusted effects of Na level on 90-day adverse outcomes (death or LT) in cirrhosis patients ($n = 2774$)

| Na (continuous) | Number of 90-day adverse outcomes (percentage) | OR, 95% CI, p value | OR, 95% CI, p value | OR, 95% CI, p value | OR, 95% CI, p value |
|-----------------|-----------------------------------------------|---------------------|---------------------|---------------------|---------------------|
|                 |                                               | Model I             | Model II            | Model III           | Model IV            |
| Na (categorical)|                                              |                     |                     |                     |                     |
| (Na 135–145 mmol/L) | 626 (22.57)                               | 0.90 (0.88,0.91)<0.001 | 0.90 (0.88,0.91)<0.001 | 0.91 (0.89,0.92)<0.001 | 0.95 (0.93,0.96)<0.001 |
| (Na > 145 mmol/L) | 336 (16.9)                                 | 1                   | 1                   | 1                   | 1                   |
| (Na 120–135 mmol/L) | 266 (38.1)                                 | 1.15 (0.59,2.24)<0.001 | 1.17 (0.60,2.29)<0.001 | 0.92 (0.47,1.83)<0.001 | 1.20 (0.58,2.50)<0.001 |
| (Na ≤ 120 mmol/L) | 11 (19)                                    | 3.02 (2.50,3.67)<0.001 | 3.02 (2.49,3.66)<0.001 | 2.64 (2.16,3.23)<0.001 | 1.78 (1.42,2.23)<0.001 |
| $p$ value for trend* | <0.001                                 |                     |                     | <0.001              | <0.001              |
| Na (continuous 5 mmol/L decrease) | 0.58 (0.53,0.63)<0.001 | 0.58 (0.53,0.63)<0.001 | 0.60 (0.56,0.67)<0.001 | 0.75 (0.68,0.83)<0.001 |
| Na (continuous 10 mmol/L decrease) | 0.34 (0.28,0.40)<0.001 | 0.34 (0.28,0.40)<0.001 | 0.30 (0.31,0.45)<0.001 | 0.57 (0.47,0.69)<0.001 |

Model I Un-adjusted;
Model II Adjusted for age, sex;
Model III Adjusted for age, sex, HE, ascites, infection;
Model IV Adjusted for age, sex, HE, ascites, infection, TBIL, INR, CR;
CI confidence interval
*Test for trend based on variables containing median value for each group

Table 4  Adjusted effects of Na level on 90-day adverse outcomes (death or LT) in the non-cirrhotic patients ($n = 1106$)

| Na (continuous) | Number of 90-day adverse outcomes (percentage) | OR,95% CI, p value | OR, 95% CI, p value | OR, 95% CI, p value | OR, 95% CI, p value |
|-----------------|-----------------------------------------------|---------------------|---------------------|---------------------|---------------------|
|                 |                                               | Model I             | Model II            | Model III           | Model IV            |
| Na (categorical)|                                              |                     |                     |                     |                     |
| (Na level 135–145 mmol/L) | 86 (7.78)                                 | 0.88 (0.84,0.94)<0.001 | 0.89 (0.84,0.94)<0.001 | 0.93 (0.88,0.99)<0.023 | 0.99 (0.93,1.05)<0.659 |
| (Na level > 145 mmol/L) | 62 (6.4)                                  | 1                   | 1                   | 1                   | 1                   |
| (Na level 120–135 mmol/L) | 3 (13.6)                                 | 2.31 (0.67,8.02)<0.187 | 2.22 (0.63,7.84)<0.215 | 1.98 (0.44,8.89)<0.371 | 1.69 (0.36,7.98)<0.505 |
| $p$ value for trend* | <0.001                                 |                     |                     | <0.001              | <0.001              |
| Na (Continuous 5 mmol/L decrease) | 0.54 (0.41,0.72)<0.001 | 0.56 (0.43,0.74)<0.001 | 0.71 (0.53,0.96)<0.023 | 0.93 (0.68,1.28)<0.659 |
| Na (Continuous 10 mmol/L decrease) | 0.29 (0.17,0.51)<0.001 | 0.32 (0.18,0.55)<0.001 | 0.51 (0.28,0.91)<0.023 | 0.87 (0.46,1.63)<0.659 |

Model I Un-adjusted;
Model II Adjusted for age, sex;
Model III Adjusted for age, sex, HE, ascites, infection;
Model IV Adjusted for age, sex, HE, ascites, infection, TBIL, INR, CR;
CI confidence interval
*Test for trend based on variables containing median value for each group
a  b

Survival time (days)

Survival time (days)

Day 1

Log-rank test p=0.0001

HR(95%CI)=3.01(2.50-3.62)

Percent survival

Percent survival

Day 4

Log-rank test p=0.0001

HR(95%CI)=2.05(1.50-2.79)

Survival time (days)

Survival time (days)

c  d

Sodium cutoff | Total number | Adverse outcome | After adjusted
<135          | 841          | 300             | 541 | A  B
>=135         | 3039         | 412             | 2827 | Percentage survival
All            | 3880         | 712             | 3168 | 81.6%

Sodium cutoff | Total number | Adverse outcome | After adjusted
<135          | 267          | 117             | 150 | 56.1%
>=135         | 182          | 45              | 137 | 75.2%
All            | 449          | 162             | 287 | 63.9%

e  f

Survival time (days)

Survival time (days)

Day 7

Log-rank test p=0.028

HR(95%CI)=1.46(1.05-2.02)

Percent survival

Percent survival

Sodium cutoff | Total number | Adverse outcome | After adjusted
<135          | 271          | 91              | 180 | 66.4%
>=135         | 220          | 54              | 186 | 75.4%
All            | 491          | 145             | 366 | 70.4%

Survival Group

Adverse outcomes Group

P=0.851
incidence of cirrhosis, ascites, and infection than the uncorrected group ($p < 0.05$) (Supplementary Table 4). Dynamic observation revealed that the Na levels on days 4 and 7 were significantly lower in patients with 90-day adverse outcomes after admission than in patients in the survival group ($p < 0.05$). However, in the 90-day adverse outcomes group, changes in Na level were not significantly different between days 4 and 7 ($p = 0.851$) (Fig. 2f).

**Discussion**

Our study population represents most inpatients with liver disease in areas with a high prevalence of HBV in China. Therefore, despite the fact that hyponatremia is a well-recognized complication of cirrhotic patients, a specific analysis of hyponatremia in patients with AoCLD had so far not been reported. The investigation of this relationship is clinically relevant, given the important physiological effects of low serum Na levels and the well-demonstrated relationship between hyponatremia and survival in a Chinese population with CLD. To the best of our knowledge, this study is the first to describe the prevalence of hyponatremia, normonatremia, and hypernatremia and their relationship with 90-day prognosis in hospitalized patients with AoCLD. We confirmed that hyponatremia is an independent risk factor for 90-day adverse outcomes in this population, which is independent of other indicators reflecting liver dysfunction, regardless of the etiology of chronic liver disease and whether patients with hepatitis B have received NUCs before admission. The risk of 90-day adverse outcomes decreased by 5%, 24%, and 42% for Na levels increased by 1, 5, and 10 mmol/L, respectively. These patients whose hyponatremia could be corrected on days 4 or 7 had a better prognosis than those whose hyponatremia could not be corrected.

In the past few decades, major studies [7, 9–12] have confirmed that hyponatremia is an independent risk factor for poor prognosis in cirrhotic patients. The European CANONIC cohort study in 2014 indicated that hyponatremia was also an independent risk factor for 90-day poor prognosis in patients with acute-on-chronic liver failure [22]. As expected, our study showed similar results in hospitalized patients with AoCLD. The LT-free mortality of patients with severe hyponatremia in our study (48%) was higher than that reported in a previous study [23]. In advanced cirrhosis, renal free water clearance function is impaired, serum Na balance is not maintained, and diluted hyponatremia occurs and is reasonably considered present; however, due to its unique human physiopathological mechanisms of systemic vasodilatation, clinicians often ignore it in daily practice [12]. Previous research showed that hyponatremia is usually accompanied by various complications in cirrhotic patients, which somewhat reflect the severity of portal hypertension [19, 24]. In our study, the incidence of liver cirrhosis, ascites, infection, hepatic encephalopathy, and jaundice in hyponatremic patients was also significantly higher, especially in patients with severe hyponatremia. Patients with severe hyponatremia tended to have a poorer liver function and higher 90-day mortality. Thus, LT should be actively considered for this population. Moreover, it is worth mentioning that 18.2% of noncirrhotic patients in our cohort still had hyponatremia and a risk of 90-day adverse outcomes. This number was only slightly lower than that in cirrhotic patients. Interestingly, after adjusting for acute decompensated events in noncirrhotic patients, the risk of 90-day adverse outcomes was statistically significant. However, the risk disappeared after the MELD score was adjusted, which suggested that Na level was not a predictor of 90-day prognosis in noncirrhotic patients. This finding was different from that in cirrhotic patients as the mechanisms of hyponatremia differ.

The European Association for the Study of the Liver guidelines (Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis) recommends that cirrhotic patients limit fluid intake and increase the dose of diuretics or use vaptans to increase the excretion of renal solute free water and other measures to improve hyponatremia when Na level is $< 130$ mmol/L [25]. In fact, high-level hyponatremia (Na level, 130–135 mmol/L) is deemed unsuitable for treatment because it is always considered a frequent and harmless feature of severe liver disease [26]. In our study, there were 86 patients with Na level of 125 mmol/L and 755 patients with Na level between $> 125$ mmol/L and $< 135$ mmol/L. However, when Na level was $< 135$ mmol/L, the risk of 90-day adverse outcomes increased, which was stricter than the 130 mmol/L recommended by the guidelines [25]. This finding suggests the necessity of hyponatremia correction in patients with AoCLD. Na level of $< 135$ mmol/L should be considered for management by clinicians. Ahluwalia et al.[27] found that cirrhotic patients can benefit from hyponatremia correction, which improves cognitive function and HRQOL. Dedicated specialist input and active treatment of severe hyponatremia can effectively reduce mortality [28]. Based on experience from the European CANONIC cohort study, most of the patients will have a clear prognosis between days 3 and 7.
of hospital admission, and clinical decisions, such as evaluation for liver transplant or discussion over goals of care, could be tailored using clinical scores [29]. However, there is limited information regarding whether hyponatremia correction in 1 week could improve the 90-day prognosis. Our study suggests that hyponatremia correction was associated with improvement in clinically relevant outcomes, regardless of day 4 or 7. The Na level increased continuously from day 4 to 7 in hyponatremic patients who survived; therefore, focusing on dynamic changes in Na level and managing hyponatremia in AoCLD in the first week after admission are crucial. Persistent abnormal Na level is often associated with an increased risk of death. This finding is supported by the fact that hyponatremia could not be corrected on day 4, and hyponatremic patients had a higher mortality rate, MELD score, and incidence of cirrhosis, infection, and ascites than those without hyponatremia. Therefore, managing complications associated with hyponatremia is essential. However, this needs to be further studied in patients with AoCLD and those with hyponatremia.

This was a large multicenter, prospective cohort study focused on areas with a high prevalence of HBV in China. All patients were followed up for 90 days, and most data were collected to ensure authenticity and integrity. In addition to the baseline material, we similarly analyzed the dynamic Na levels on days 4 and 7 after admission.

This study has some limitations. First, there were some missing values for the dynamic Na level. Second, owing to the nature of observational studies and various patient conditions, therapy measures of hyponatremia were not unified among the centers; however, we employed a unified standard of diagnosis and treatment for hyponatremia [30].

In conclusion, our study showed that hyponatremia is an independent risk factor for 90-day adverse outcomes in hospitalized patients with AoCLD. Elevated Na levels reduced the risk of 90-day adverse outcomes, and failure to correct hyponatremia in a week after admission was often associated with increased mortality. Therefore, clinicians should focus on hyponatremia in patients with AoCLD and actively manage its related complications in daily clinical practice for hyponatremia correction.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12072-021-10282-8.

Acknowledgements We thank the following Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C) members and participants for the contributions to this study: Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre, Fudan University—Jiefei Wang, Wei Yuan; Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University—Shan Yin, Wenyi Gu, Yan Zhang, Tongyu Wang, Dandan Wu, Fuchen Dong, Bo Zeng, Liuying Chen, Shijin Wang; Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Zeng Weituo; Centre of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University—Qun Zhang, Yixin Hou, Yuxin Li, Yunyi Huang; Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University)—Shuning Sun, Wenting Tan, Xiaomai Xiang, Yunjie Dan; Department of Infectious Disease, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University—Jun Chen, Ruoqian Chen, Liuyan Long; Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology—Jing Liu, Ling Xu, Shue Xiong, Yan Xiong, Congcong Zou; Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University—Renjie Ouyang, Congyan Zhu; Department of Hepatology, First Hospital of Jilin University—Chang Jiang, Xiaoyu Wen, Na Gao, Chunyan Liu; Department of Infectious Disease, Taihe Hospital, Hubei University of Medicine—Ying Wang, Qing Lei, Sen Luo; Department of Infectious Disease, The First Hospital of Zhejiang University—Haotang Ren; Department of Infectious Diseases and Hepatology, Second Hospital of Shandong University—Tao Li, Xuanqiong Fang, Jing Li, Ziyu Wang; Liver Disease Centre, First Affiliated Hospital of Xijinjiang Medical University—Rongqiong Zheng, Fangrong Jie, Nan Li; Department of Infectious Disease, Henan Provincial People’s Hospital—Huiming Jin; Infectious Disease Center, Affiliated Hospital of Logistics University of People’s Armed Police Force—Hai Li, Qing Zhang, Xuequn Zheng; and Department of Infectious Disease, Fuzhou General Hospital of Nanjing Military Command—Shaoyang Wang, Taofa Lin.

Author contributions XM, HL, XW, GD, and YH contributed equally and share first authorship. HL, GD, XW, XZ, YH, JC, ZM, YG, FL, XL, YS, YZ, HY, and ZQ obtained the funding. ZQ and WY designed the study. LQ, WG, YZ, XX, YZ, SS, YH, QZ, YK, CZ, JC, ZH, BL, XJ, GZ, HW, YC, SL, NG, CL, JL, TL, RZ, XZ, and HR collected the data. WZ directed statistical analysis. XM drafted the manuscript. ZQ and WY contributed to the critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript.

Funding This research was supported by the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support and Shanghai Hospital Development Center Funding (SHDC-2020CR1037B); the National Science and Technology Major Project (2018ZX10302206, 2018ZX10723203, 2018ZX10725506); the Science Foundation of Shanghai Municipal Health Commission (20184Y0058); and the National Key Research and Development Program of China (2017YFC0908104).

Data and material availability All data included in this study are available upon request by contact with the corresponding author.

Code availability All codes used in this study followed the manuals of each R package, which are fully open accessed.

Declarations

Conflict of interest Xue Mei, Hai Li, Guohong Deng, Xianbo Wang, Xin Zheng, Yan Huang, Jinjun Chen, Zhongji Meng, Yanhang Gao, Feng Liu, Xiaobo Lu, Yu Shi, Yubao Zhong, Huadong Yan, Weituo Zhang, Liang Qiao, Wenyi Gu, Yan Zhang, Xiaomei Xiang, Yi Zhou, Shuning Sun, Yixin Hou, Qun Zhang, Yan Xiong, Congcong Zou, Jun Chen, Zebing Huang, Beiling Li, Xiuhua Jiang, Guotao Zhong, Haiyu Wang, Yuanyuan Chen, Sen Luo, Na Gao, Chunyan Liu, Jing Li, Tao Li, Rongqiong Zheng, Xinyi Zhou, Haotang Ren, Wei Yuan, Zhiping Qian declare that they have no conflict of interest.
Ethics approval  The ethics committee of Ren Ji Hospital (the lead center of the CATCH-LIFE study), School of Medicine, Shanghai Jiao-tong University (Shanghai, China) approved the study [ethics code: (2014)148k and (2016)142k].

Consent to participate  Written informed consent was obtained from all patients.

Consent for publication  All authors of this manuscript have read and approved the final submitted version and are aware that they are listed as an author on this paper.

References

1. Wang S, Toy M, Hang Pham TT, et al. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the US, 2010–2019. PLoS One. 2020;15:e0239393
2. Seto WK, Mandell MS. Chronic liver disease: global perspectives and future challenges to delivering quality health care. PLoS One. 2021;16:e0243607
3. GBD. Cirrhosis Collaborators (2020) The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2017;5(3):245–266
4. Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis. Eur J Gastroenterol Hepatol. 2021;33:114–115
5. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:2
6. Russell W, Erick E, Richard F, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–96
7. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–1026
8. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336–343
9. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–1660
10. Lenci I, Milana M, Grassi G, et al. Natriemia and liver transplantation: the right amount of salt for a good recipe. World J Hepatol. 2012;4:919–930
11. Neuberger J, Gimson A, Davies M, Liver Advisory Group, et al. UK blood and transplant. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut. 2008;57:252–257
12. Alukal JJ, John S, Thuluvath PJ. Hyponatremia in cirrhosis: an update. Am J Gastroenterol. 2020;115(11):1775–1785
13. Ahluwalia V, Wade James B, Leroy T, et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol. 2013;59:467–473
14. Henrikus E, Ou G, Kinney B, et al. Prevalence, timing, causes, and outcomes of hyponatremia in hospitalized orthopaedic surgery patients. J Bone Jt Surg Am. 2015;97:1824–1832
15. Mannheimer B, Skov J, Falhammar H, et al. Sex-specific risks of death in patients hospitalized for hyponatremia: a population-based study. Endocrine. 2019;66:660–665
16. Qiao L, Wang X, Deng G, et al. Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. BMJ Open. 2021;11:e037793
17. Zhang Y, Xu BY, Wang XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. Clin Gastroenterol Hepatol. 2020;18:2564–72.e1
18. Gu WY, Xu BY, Zheng X, et al. Acute-on-chronic liver failure in China: rationale for developing a patient registry and baseline characteristics. Am J Epidemiol. 2018;187:1829–1839
19. Sterns RH. Disorders of plasma sodium—causes, consequences, and correction. N Engl J Med. 2015;372:55–65
20. George JC, Zafar W, Bucaloiu ID, et al. Risk factors and outcomes of rapid correction of severe hyponatremia. Clin J Am Soc Nephrol. 2018;13:984–992
21. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009;122:857–865
22. Cárdenas A, Solà E, Rodríguez E, CANONIC study investigators of the EASL-CLIF Consortium, et al. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Crit Care. 2014;18:700
23. Krummel T, Prinz E, Metten MA, et al. Prognosis of patients with severe hyponatraemia is related not only to hyponatraemia but also to comorbidities and to medical management: results of an observational retrospective study. BMC Nephrol. 2016;17:159
24. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802–810
25. European Association for the Study of the Liver (2018) Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69:406–60.
26. John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015;21:3197–3205
27. Ahluwalia V, Heuman DM, Feldman G, et al. Persistent ascites and correction. N Engl J Med. 2015;372:55–65
28. Garrahy A, Cuesta M, Murphy B, et al. Active management of oedema in cirrhosis. J Hepatol. 2015;62:75–82
29. Krummel T, Prinz E, Metten MA, et al. Prognosis of patients with severe hyponatraemia is related not only to hyponatraemia but also to comorbidities and to medical management: results of an observational retrospective study. BMC Nephrol. 2016;17:159
30. Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–553
31. John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015;21(11):3197–3205

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Xue Mei¹ · Hai Li²,³ · Guohong Deng⁴ · Xianbo Wang⁵ · Xin Zheng⁶ · Yan Huang⁷ · Jinjun Chen⁸ · Zhongji Meng⁹ · Yanhang Gao¹⁰ · Feng Liu¹¹ · Xiaobo Lu¹² · Yu Shi¹³,¹⁴,¹⁵ · Yubao Zheng¹⁶ · Huadong Yan¹⁷ · Weituo Zhang¹⁸ · Liang Qiao²,³ · Wenyi Gu²,³ · Yan Zhang²,³ · Xiaomei Xiang⁴ · Yi Zhou⁴ · Shuning Sun⁶ · Yixin Hou⁵ · Qun Zhang⁵ · Yan Xiong⁶ · Congcong Zou⁶ · Jun Chen⁷ · Zebing Huang⁷ · Beiling Li⁸ · Xiuhua Jiang⁸ · Guotao Zhong⁸ · Haiyu Wang⁸ · Yuanyuan Chen⁹ · Sen Luo⁹ · Na Gao¹⁰ · Chunyan Liu¹⁰ · Jing Li¹¹ · Tao Li¹¹ · Rongjiong Zheng¹² · Xinyi Zhou¹² · Haotang Ren¹³,¹⁴,¹⁵ · Wei Yuan¹ · Zhiping Qian¹

¹ Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre (Fudan University), 2901 Cao Lang Road, Jinshan District, Shanghai 201508, China
² Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
³ Shanghai Institute of Digestive Disease, Key Laboratory of Gastroenterology and Hepatology, Chinese Ministry of Health (Shanghai Jiao Tong University), Shanghai, China
⁴ Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China
⁵ Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
⁶ Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁷ Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China
⁸ Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
⁹ Department of Infectious Diseases, Hubei Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Shiyan, China
¹⁰ Department of Hepatology, The First Hospital of Jilin University, Changchun, China
¹¹ Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Jinan, China
¹² Infectious Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
¹³ The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China
¹⁴ Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, Hangzhou, China
¹⁵ National Clinical Research Center of Infectious Disease, Hangzhou, China
¹⁶ Department of Infectious Diseases, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
¹⁷ Department of Hepatology, Number 2 Hospital, Ningbo, China
¹⁸ Clinical Research Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China